Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Takeshi
T
Kashima
Yoshio
Y
Ohno
Masaaki
M
Tachibana
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D011006:Pneumatosis Cystoides Intestinalis / Q000175:diagnosis* / Q000209:etiology; D011169:Portal Vein / Q000473:pathology*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib